VJHemOnc is committed to improving our service to you

ISA 2020 | Tocilizumab for AA amyloidosis

VJHemOnc is committed to improving our service to you

Luis Quintana

Anti-interleukin-6 receptor, tocilizumab, has demonstrated improvements in the clinical symptoms of patients with AA amyloidosis, being associated with regression of amyloid deposition. Luis Quintana, MD, PhD, Hospital Clínic de Barcelona, Barcelona, Spain discusses the use of this agent for AA amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter